These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 7937818)

  • 21. Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells.
    Gillies SD; Reilly EB; Lo KM; Reisfeld RA
    Proc Natl Acad Sci U S A; 1992 Feb; 89(4):1428-32. PubMed ID: 1741398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting of interleukin-2 to human MK-1-expressing carcinoma by fusion with a single-chain Fv of anti-MK-1 antibody.
    Matsumoto H; Liao S; Arakawa F; Ueno A; Abe H; Awasthi A; Kuroki M; Kuroki M
    Anticancer Res; 2002; 22(4):2001-7. PubMed ID: 12174877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination therapy with interleukin-2 and antitumor monoclonal antibodies.
    Sondel PM; Hank JA
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S121-7. PubMed ID: 9457407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
    Prapa M; Caldrer S; Spano C; Bestagno M; Golinelli G; Grisendi G; Petrachi T; Conte P; Horwitz EM; Campana D; Paolucci P; Dominici M
    Oncotarget; 2015 Sep; 6(28):24884-94. PubMed ID: 26298772
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody-interleukin 2 fusion proteins: a new approach to cancer therapy.
    Reisfeld RA; Gillies SD
    J Clin Lab Anal; 1996; 10(3):160-6. PubMed ID: 8731505
    [No Abstract]   [Full Text] [Related]  

  • 26. Fractalkine gene therapy for neuroblastoma is more effective in combination with targeted IL-2.
    Zeng Y; Jiang J; Huebener N; Wenkel J; Gaedicke G; Xiang R; Lode HN
    Cancer Lett; 2005 Oct; 228(1-2):187-93. PubMed ID: 15953676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro.
    Hank JA; Surfus J; Gan J; Chew TL; Hong R; Tans K; Reisfeld R; Seeger RC; Reynolds CP; Bauer M
    J Immunother Emphasis Tumor Immunol; 1994 Jan; 15(1):29-37. PubMed ID: 8110728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin.
    Honsik CJ; Jung G; Reisfeld RA
    Proc Natl Acad Sci U S A; 1986 Oct; 83(20):7893-7. PubMed ID: 3094017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2.
    Hank JA; Robinson RR; Surfus J; Mueller BM; Reisfeld RA; Cheung NK; Sondel PM
    Cancer Res; 1990 Sep; 50(17):5234-9. PubMed ID: 2386933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inflammatory response and treatment tolerance of long-term infusion of the anti-GD
    Ceylan K; Jahns LJ; Lode BN; Ehlert K; Kietz S; Troschke-Meurer S; Siebert N; Lode HN
    Pediatr Blood Cancer; 2018 Jun; 65(6):e26967. PubMed ID: 29350486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant human prolactin improves antitumor effects of murine natural killer cells in vitro and in vivo.
    Sun R; Wei H; Zhang J; Li A; Zhang W; Tian Z
    Neuroimmunomodulation; 2002-2003; 10(3):169-76. PubMed ID: 12481157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases.
    Cameron RB; McIntosh JK; Rosenberg SA
    Cancer Res; 1988 Oct; 48(20):5810-7. PubMed ID: 3262413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy.
    Becker JC; Varki N; Gillies SD; Furukawa K; Reisfeld RA
    J Clin Invest; 1996 Dec; 98(12):2801-4. PubMed ID: 8981927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues.
    Vujanovic NL; Yasumura S; Hirabayashi H; Lin WC; Watkins S; Herberman RB; Whiteside TL
    J Immunol; 1995 Jan; 154(1):281-9. PubMed ID: 7995947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of human colon cancer growth by antibody-directed human LAK cells in SCID mice.
    Takahashi H; Nakada T; Puisieux I
    Science; 1993 Mar; 259(5100):1460-3. PubMed ID: 8451642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
    Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
    Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of GD2 peptide mimotope DNA vaccines effective against spontaneous neuroblastoma metastases.
    Fest S; Huebener N; Weixler S; Bleeke M; Zeng Y; Strandsby A; Volkmer-Engert R; Landgraf C; Gaedicke G; Riemer AB; Michalsky E; Jaeger IS; Preissner R; Förster-Wald E; Jensen-Jarolim E; Lode HN
    Cancer Res; 2006 Nov; 66(21):10567-75. PubMed ID: 17079481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group.
    Frost JD; Hank JA; Reaman GH; Frierdich S; Seeger RC; Gan J; Anderson PM; Ettinger LJ; Cairo MS; Blazar BR; Krailo MD; Matthay KK; Reisfeld RA; Sondel PM
    Cancer; 1997 Jul; 80(2):317-33. PubMed ID: 9217046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD
    Mueller I; Ehlert K; Endres S; Pill L; Siebert N; Kietz S; Brock P; Garaventa A; Valteau-Couanet D; Janzek E; Hosten N; Zinke A; Barthlen W; Varol E; Loibner H; Ladenstein R; Lode HN
    MAbs; 2018 Jan; 10(1):55-61. PubMed ID: 29120699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients.
    Albertini MR; Hank JA; Schiller JH; Khorsand M; Borchert AA; Gan J; Bechhofer R; Storer B; Reisfeld RA; Sondel PM
    Clin Cancer Res; 1997 Aug; 3(8):1277-88. PubMed ID: 9815810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.